Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


GREY:CLAZF - Post by User

Comment by SeeDonRunon Oct 10, 2021 12:23am
183 Views
Post# 33992750

RE:Try Again

RE:Try Again
Red~One wrote:
Would someone please explain how a short seller, or a day trader or a swingtrader could make money on CLAS when daily volume is low, volatility is low/non existant and the liklihood of big news is also low since the company have already  made it very clear what the timeline is going forward. 
If CLAS is under attack from shorts there must be some way to prove it

Naked shorting is not recorded day to day so won't appear on charts.  Day and swing traders won't be set up to do naked shorting, only hedge funds and the like are.  As well, once set up it's not a singular event rather a day in day out sort of deal where the pressure can be kept up for years even. 

You ask for proof but really, given the prevelance of naked shorting amongst small Canadian companies and the fact they are not recorded day to day it would be surprising to find Claritas was not a target by some hedge fund.  The fact that the share price was driven up upon us opening after months of being shut down is a pretty solid indication that there were a lot of short coverings occuring at that time.

https://magazine.cim.org/en/news/2021/regulators-to-take-steps-against-short-selling-en/


<< Previous
Bullboard Posts
Next >>